Trials / Conditions / Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

19 registered clinical trials studyying Chronic Hepatitis C Virus Infection.

Status	Trial	Sponsor	Phase
Completed	Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients NCT04391985	Beni-Suef University	Phase 1 / Phase 2
Completed	ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants NCT04387539	Beni-Suef University	Phase 1 / Phase 2
Completed	Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 NCT04387526	Beni-Suef University	Phase 2 / Phase 3
Completed	Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infec NCT04382937	PharmaEssentia	Phase 3
Completed	Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients NCT04385407	Beni-Suef University	Phase 2
Completed	A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ri NCT02292719	AbbVie	Phase 2
Withdrawn	Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Bir NCT01813266	Intermountain Health Care, Inc.	—
Completed	Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and NCT01708889	Bristol-Myers Squibb	Phase 1
Unknown	Hepatitis C in Renal Transplant Recipients NCT02108301	Prof. Dr. Alice Schmidt	Phase 4
Terminated	A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genot NCT01080222	Vertex Pharmaceuticals Incorporated	Phase 2
Completed	A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic H NCT01121731	Digna Biotech S.L.	Phase 1 / Phase 2
Completed	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of AB NCT00851890	AbbVie (prior sponsor, Abbott)	Phase 2
Completed	FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy NCT00606528	University Health Network, Toronto	—
Completed	Study of CTS-1027 in Hepatitis C Patients NCT00570336	Conatus Pharmaceuticals Inc.	Phase 2
Unknown	Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients NCT00563173	Tripep AB	Phase 1 / Phase 2
Withdrawn	Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders NCT00255359	Hadassah Medical Organization	Phase 1
Unknown	Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT NCT00294489	Hadassah Medical Organization	—
Completed	sgp130 in Chronic Human Liver Disease NCT00770198	Erasme University Hospital	—
Completed	PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed NCT00215865	Hepatitis Resource Network	Phase 3